|
Reckitt Benckiser Group PLC on Wednesday reported revenue growth in the third quarter, boosted by strong Durex sales in China. The Slough, England-based consumer health and hygiene products company behind Durex, Nurofen and Vanish said net revenue rose to £3.61 billion in the third quarter of 2025, up 4.5% on a reported basis from £3.46 billion it had announced a year ago, and up 7.0% like-for-like. Core net revenue growth was 6.7% in the third quarter, boosted by ‘stand-out’ growth in emerging markets amid a return to growth in North America and Europe. Meanwhile, Reckitt cited a ‘strong’ quarter in China, highlighting performances by Dettol, Durex, and Intima. ‘Durex grew strongly across emerging markets, led by China where the strength of the brand and recent innovations have continued to drive positive price/mix and share gains,’ Reckitt said. The company highlighted that it ‘continued to drive encouraging sell out performance in India’ despite LfL net revenue growth being impacted by a goods & services tax regime change in September. India in September announced a simplified tax structure, which Reckitt noted for ‘tempering sell in growth’. Performance across Latin America was mixed, with a softer consumer environment in Brazil offset by growth across all categories in Mexico. The company maintained its 2025 outlook as it anticipates another year of growth in adjusted diluted earnings per share. Reckitt continues to expect like-for-like net revenue growth of 3% to 4% in 2025. Further, Reckitt said it completed the first £250 million tranche of its £1 billion share buyback programme, buying back 4.4 million shares at an average price of £56.23 each between July 28 and Tuesday. Reckitt confirmed on Wednesday it had started the second tranche which will run until January 30 at the latest. Reckitt Benckiser shares were down 0.2% at 5,864.00 pence each on Wednesday morning in London. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
